[
  {
    "title": "News",
    "link": "https://investors.cullinantherapeutics.com/news-releases",
    "timestamp": "unknown"
  },
  {
    "title": "Contact Us",
    "link": "https://www.cullinanoncology.com/contact",
    "timestamp": "unknown"
  },
  {
    "title": "Overview",
    "link": "https://investors.cullinantherapeutics.com/",
    "timestamp": "unknown"
  },
  {
    "title": "Events and Presentations",
    "link": "https://investors.cullinantherapeutics.com/events",
    "timestamp": "unknown"
  },
  {
    "title": "SEC Filings",
    "link": "https://investors.cullinantherapeutics.com/sec-filings",
    "timestamp": "unknown"
  },
  {
    "title": "Stock Information",
    "link": "https://investors.cullinantherapeutics.com/stock-information",
    "timestamp": "unknown"
  },
  {
    "title": "Corporate Governance",
    "link": "https://investors.cullinantherapeutics.com/corporate-governance",
    "timestamp": "unknown"
  },
  {
    "title": "Investor FAQs",
    "link": "https://investors.cullinantherapeutics.com/faqs",
    "timestamp": "unknown"
  },
  {
    "title": "Email Alerts",
    "link": "https://investors.cullinantherapeutics.com/email-alerts",
    "timestamp": "unknown"
  },
  {
    "title": "Home",
    "link": "https://www.cullinanoncology.com/",
    "timestamp": "unknown"
  },
  {
    "title": "About Cullinan",
    "link": "https://cullinantherapeutics.com/about/",
    "timestamp": "unknown"
  },
  {
    "title": "Leadership",
    "link": "https://cullinantherapeutics.com/leadership/",
    "timestamp": "unknown"
  },
  {
    "title": "Partnerships",
    "link": "https://cullinantherapeutics.com/partnerships/",
    "timestamp": "unknown"
  },
  {
    "title": "R&D",
    "link": "https://cullinantherapeutics.com/research-development/",
    "timestamp": "unknown"
  },
  {
    "title": "Programs",
    "link": "https://cullinantherapeutics.com/programs/",
    "timestamp": "unknown"
  },
  {
    "title": "Pipeline",
    "link": "https://cullinantherapeutics.com/pipeline/",
    "timestamp": "unknown"
  },
  {
    "title": "Patient Programs",
    "link": "https://cullinantherapeutics.com/patient-programs/",
    "timestamp": "unknown"
  },
  {
    "title": "Clinical Trials",
    "link": "https://cullinantherapeutics.com/clinical-trials/",
    "timestamp": "unknown"
  },
  {
    "title": "Our People",
    "link": "https://cullinantherapeutics.com/people/",
    "timestamp": "unknown"
  },
  {
    "title": "Careers",
    "link": "https://cullinantherapeutics.com/careers/",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "YearAll20252024202320222021202020192017Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 Wo",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung CancerJuly 22, 2",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung CancerJuly 22, 2",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-acceptance",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Aut",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-licenses-rights-velinotamig-clinical-stage",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Aut",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-licenses-rights-velinotamig-clinical-stage",
    "timestamp": "unknown"
  },
  {
    "title": "Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical OncologyJune 1, 2025",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-pivotal",
    "timestamp": "unknown"
  },
  {
    "title": "Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/taiho-oncology-and-cullinan-therapeutics-announce-pivotal",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare ConferenceMay",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-host-analyst-and-investor-event-2025-asco",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-host-analyst-and-investor-event-2025-asco",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-taiho-pharmaceutical-and-taiho-oncology",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-provides-corporate-update-and-reports-3",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-provides-corporate-update-and-reports-3",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj\u00f6gren\u2019s Disease i",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-initiate-study-cln-978-bispecific-cd19-t",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj\u00f6gren\u2019s Disease i",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-initiate-study-cln-978-bispecific-cd19-t",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-present-results-rezilient1-phase-12-trial",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-present-results-rezilient1-phase-12-trial",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administ",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-receives-approval-european-medicines",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administ",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-receives-approval-european-medicines",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-provides-corporate-update-and-reports-2",
    "timestamp": "unknown"
  },
  {
    "title": "Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results",
    "link": "https://investors.cullinantherapeutics.com/news-releases/news-release-details/cullinan-therapeutics-provides-corporate-update-and-reports-2",
    "timestamp": "unknown"
  },
  {
    "title": "PaginationCurrent page1Page2Next pagenext \u203aLast pagelast \u00bb",
    "link": "https://investors.cullinantherapeutics.com/news-releases?page=0",
    "timestamp": "unknown"
  },
  {
    "title": "Current page1",
    "link": "https://investors.cullinantherapeutics.com/news-releases?page=0",
    "timestamp": "unknown"
  },
  {
    "title": "Page2",
    "link": "https://investors.cullinantherapeutics.com/news-releases?page=1",
    "timestamp": "unknown"
  },
  {
    "title": "Next pagenext \u203a",
    "link": "https://investors.cullinantherapeutics.com/news-releases?page=1",
    "timestamp": "unknown"
  },
  {
    "title": "Last pagelast \u00bb",
    "link": "https://investors.cullinantherapeutics.com/news-releases?page=1",
    "timestamp": "unknown"
  },
  {
    "title": "Follow UsSite - Social",
    "link": "https://www.linkedin.com/company/CullinanTx",
    "timestamp": "unknown"
  },
  {
    "title": "Site - Social",
    "link": "https://www.linkedin.com/company/CullinanTx",
    "timestamp": "unknown"
  },
  {
    "title": "Connect With Us",
    "link": "https://cullinantherapeutics.com/contact/",
    "timestamp": "unknown"
  },
  {
    "title": "Terms of Use",
    "link": "https://cullinantherapeutics.com/terms-of-use/",
    "timestamp": "unknown"
  },
  {
    "title": "Privacy Notice",
    "link": "https://cullinantherapeutics.com/privacy-notice/",
    "timestamp": "unknown"
  },
  {
    "title": "Accessibility Policy",
    "link": "https://cullinantherapeutics.com/accessibility/",
    "timestamp": "unknown"
  }
]